VIXOTRIGINE
Other Neuropathic Pain
BiogenSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Other Neuropathic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | BB |
NEPENTHE Nova Scotia Health Authority | Phase 4 | BB |
Dfn-15 Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | BB |
Naltrexone Emory University | Phase 4 | BB |
FENTANYL Cephalon | Phase 3 | B |
View all 20 →
Same molecule, other indications
VIXOTRIGINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →